S. LaRosa

发表

S. Opal, S. LaRosa, 2011, Critical care clinics.

K. Tomecki, S. LaRosa, Ravindran A Padmanabhan, 2005, Dermatologic clinics.

Immune Aspects of Sepsis and Hope for New Therapeutics

S. Opal, S. LaRosa, 2012, Current Infectious Disease Reports.

Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient.

K. Chapin, L. Mermel, P. Chan, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Drotrecogin alfa (activated) in severe sepsis--authors' reply.

A. Kalil, S. LaRosa, 2013, The Lancet. Infectious diseases.

Use of corticosteroids in the sepsis syndrome: what do we know now?

S. LaRosa, 2005, Cleveland Clinic journal of medicine.

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

R. Wunderink, S. Opal, E. Abraham, 2009, Critical care.

Conflict of interest: authorship issues predominate.

S. LaRosa, 2002, Archives of internal medicine.

Removal of COVID-19 Spike Protein, Whole Virus, Exosomes, and Exosomal MicroRNAs by the Hemopurifier® Lectin-Affinity Cartridge in Critically Ill Patients With COVID-19 Infection

D. Amundson, S. LaRosa, R. de Necochea-Campion, 2021, Frontiers in Medicine.

Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutinin

C. Roux, S. LaRosa, Melanie Gooldy, 2022, bioRxiv.

Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.

J. Helterbrand, C. Fisher, A. Simpson, 2006 .

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.

A. Kalil, S. LaRosa, 2012, The Lancet. Infectious diseases.

Tissue Factor Pathway Inhibitor and Anitithrombin Trial Results

S. Opal, S. LaRosa, 2005 .

Clinical Trials of Novel Anticoagulants for Severe Sepsis: A Tale of Three Molecules

S. Opal, S. LaRosa, 2004 .

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

G. Bernard, J. Vincent, J. Parrillo, 2013, Critical care medicine.

White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens.

J. Bartlett, R. Bonomo, R. Lewis, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical and laboratory diagnosis of central nervous system histoplasmosis.

R. Fader, S. LaRosa, Travea McGhie, 2012, The American journal of medicine.

The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)

Gary Garber, Jay Steingrub, Pierre-François Laterre, 2001 .

Sepsis strategies in development.

S. Opal, S. LaRosa, 2008, Clinics in chest medicine.

Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis

M. Tidswell, S. LaRosa, 2011, Expert review of anti-infective therapy.

Strategies to treat sepsis: old and new

S. Opal, S. LaRosa, 2011 .

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

J. Vincent, D. Angus, R. Schein, 2013, JAMA.

Heparin-Induced Extracorporeal Lipoprotein Fibrinogen Apheresis

S. Opal, S. LaRosa, 2008 .

Efficacy and safety of recombinant human activated protein C for severe sepsis

J. Helterbrand, J. Barkun, G. Bernard, 2003 .

Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia

S. Calvano, S. Lowry, S. Coyle, 2004, Shock.

Activated protein C for H1N1 influenza? More work to do!

S. LaRosa, 2010, Critical care.

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*

S. Opal, A. Wittek, M. Tidswell, 2010, Critical care medicine.

Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials*

S. Opal, D. Angus, V. Ranieri, 2016, Critical care medicine.

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

R. Schein, J. Dhainaut, D. Maki, 2003, Critical care medicine.

Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-&agr; Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock: Randomized, Double-Blind, Placebo-Controlled Phase IIb Study*

M. Levy, G. Bernard, J. Vincent, 2014, Critical care medicine.

Objective: This trial compared the efficacy/safety of two IV doses of AZD9773, a polyclonal antibody to tumor necrosis factor-α, in adult patients with severe sepsis/septic shock

M. Levy, G. Bernard, J. Vincent, 2014 .

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

G. Bernard, J. Dhainaut, S. Opal, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.

S. Opal, R. Wunderink, C. Doig, 2011, American journal of respiratory and critical care medicine.

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?

S. Opal, S. LaRosa, 2013, American journal of respiratory and critical care medicine.

Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis

S. Opal, A. Kalil, S. LaRosa, 2011, Shock.

Phase 2 trial of eritoran tetrasodium ( E 5564 ) , a Toll-like receptor 4 antagonist , in patients with severe sepsis *

S. Opal, A. Wittek, M. Tidswell, 2009 .

Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from Blood by Heparin-Functional Hemoperfusion Media

R. Ward, K. Mccrea, S. LaRosa, 2014, PloS one.

Early goal-directed therapy in the treatment of severe sepsis and septic shock

J. Helterbrand, P. Singer, T. Evans, 2002 .

Sepsis: menu of new approaches replaces one therapy for all.

S. LaRosa, 2002, Cleveland Clinic journal of medicine.

Year in review 2008: Critical Care - sepsis

S. Opal, S. LaRosa, 2009, Critical care.

Antibiotics: what's new?

K. Tomecki, S. LaRosa, 2004, Cutis (New York, N.Y.).

At the heart of the matter.

Arun K. Singh, S. LaRosa, M. Connor, 2009, The American journal of medicine.

Efficacy and safety of recombinant human activated protein C for severe sepsis.

J Ean, ngel, J Effrey, 2001, The New England journal of medicine.

Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?

A. Arroliga, R. Avery, D. Longworth, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.

J. Helterbrand, S. Opal, W. Chaowagul, 2006 .

Time for Well-Powered Controlled Prospective Studies to test a Causal Role for Herpes Viruses in Alzheimer Using Anti-Herpes Drugs.

M. Pericak-Vance, P. Goldschmidt-Clermont, S. LaRosa, 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.

A. Kalil, S. LaRosa, 2012, The Lancet. Infectious diseases.

M. Levy, G. Bernard, J. Vincent, 2014, Critical Care Medicine.